Activity of plasma proteolytic systems was studied in outbred albino rats with acute renal failure. The possibility of treating this disorder with acute phase protein alpha-1-acid glycoprotein was evaluated. Acute renal failure was induced by single subcutaneous injection of mercury chloride (II). The parameters were evaluated on day 5 postinjection. alpha-1-Acid glycoprotein in a dose of 150 mg/kg was administered 3 times. Acute renal failure was accompanied by activation of the complement system and fibrin formation (with factors for the intrinsic and common pathways of blood coagulation) and inhibition of the fibrinolytic system and antithrombin activity. Treatment with glycoprotein was followed by partial recovery of fibrin formation and complement system. These changes were probably related to accumulation of glycoprotein in the renal tissue and in situ protective effect.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10517-009-0629-5 | DOI Listing |
Ren Fail
December 2025
Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.
Background: IgA nephropathy (IgAN) presents a challenging spectrum of outcomes, often complicated by intrarenal arterial/arteriolar lesions (IALs) in affected individuals. Despite their clinical relevance, existing criteria for classifying and assessing the severity of these lesions remain undefined. This study aimed to establish semi-quantitative assessment criteria for grading IALs and to evaluate their prognostic significance in patients with IgAN.
View Article and Find Full Text PDFJ Am Coll Cardiol
March 2025
Ciccarone Center for Prevention of Cardiovascular Disease, Johns Hopkins Medicine, Baltimore, Maryland, USA; American Heart Association Tobacco Regulation and Addiction Center, Dallas, Texas, USA. Electronic address:
Background: Cigarette smoking is a strong risk factor for cardiovascular harm.
Objectives: The study sought to explore the detailed relationships between smoking intensity, pack-years, and time since cessation with inflammation, thrombosis, and subclinical atherosclerosis markers of cardiovascular harm.
Methods: We included 182,364 participants (mean age 58.
BMJ Open
March 2025
Department of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria.
Objectives: To investigate homocysteine (Hcy) levels in individuals with chronic kidney disease (CKD), hypertension and a healthy Nigerian population, and to assess their association with cardiovascular disease (CVD) risk.
Setting: The study was conducted using data from the Ibadan CRECKID (Cardiovascular and Renal Event in People with Chronic Kidney Disease) study in Nigeria.
Participants: A total of 420 adults (aged 18+) categorised into three groups: individuals with stage 2 CKD or higher, hypertensive non-CKD individuals and normotensive individuals.
J Pharm Pract
March 2025
Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
Cefazolin-induced encephalopathy and seizures are possibly related to excessive dosing; especially in those with renal dysfunction. This report aims to highlight the importance of dose adjustments of cefazolin in patients with diminished renal function. An 87-year-old female with a history of cognitive impairment, remote cerebellar infarcts, hypertension, and hypothyroidism presented with acute delirium associated with a urinary tract infection.
View Article and Find Full Text PDFJ Am Acad Orthop Surg Glob Res Rev
March 2025
From the Department of Orthopaedic Surgery, Boston Medical Center Pl, Boston, MA.
Compartment syndrome is an orthopaedic emergency with moderate-to-severe sequela (pain, muscle contracture, nerve damage, infection, rhabdomyolysis, renal failure, etc.) if inadequately treated and can be difficult to diagnose in a timely fashion. Further complicating timely diagnosis are atypical presentations resulting in compartment syndrome.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!